Trusted Preclinical Research Services

Dive Deep to advance your preclinical oncology drug development

Embarking on a drug discovery journey can feel like exploring uncharted territory. But with TD2 as your trusted preclinical oncology partner, you can be confident that you’ll find your way to the clinic. Our team of experienced researchers has extensive knowledge in solid and hematologic tumors, immuno-oncology, and adoptive cell therapy. We provide a consultative approach to ensure the best results and continuity with your future clinical and regulatory strategy. With over 600 first-in-human studies under our belt, we have the specialized oncology knowledge to design and execute your preclinical program to support your clinical and regulatory goals. Trust TD2 for optimal study design and rapid study initiation.

At TD2, we know that time is of the essence when it comes to drug discovery. That’s why we continue to expand our preclinical service offerings. New services include humanized immune checkpoint inhibitor mouse models, diet-induced obesity mouse models, and metabolomic analysis services. These models are designed to provide you with the data you need to make informed decisions about your program and move your treatments to the clinic as quickly as possible. With TD2, you’ll have a partner that is committed to your success every step of the way.

Comprehensive preclinical services.

Personalized, Expert Support

Learn more about our Preclinical services.

Contact our experts to help advance your cancer therapeutic with our trusted preclinical research services.

Optimal Study Design to Advance Your Therapeutic Program

Syngeneic mouse models

Unlock the full potential of your research with fully characterized syngeneic mouse models featuring detailed immune profiling from TD2. Our syngeneic tumor models are extensively characterized for gene expression, baseline populations of TILs, and response to common immune checkpoint inhibitors, providing you with the confidence you need to make informed decisions about your research.

We take a consistent host approach, defining the microbiome through 16S rRNA gene sequencing before the study even begins, ensuring a known and stable host from start to finish. Our multi-parameter flow cytometry allows us to identify effector cells and characterize immune cell population changes post-treatment, giving you a comprehensive view of your results. See available models

CAR-T capabilities

With over 100 studies completed and strong experience with CAR T-cell handling and processing, TD2 has the specialized oncology knowledge to design and execute your program to meet your goals.

We offer flexibility with cryopreserved or fresh CAR T-cells and use fluorescent-based counting methods to accurately determine cell count and viability, giving you the data you need to make informed decisions. Our expertise in adoptive cell therapy means we can help you design a program that maximizes your chances of success. Choose TD2 for the knowledge and experience you need to achieve your adoptive cell therapy goals.  See available cell lines

Humanized mice

• Human PBMCs or effector cell engraftment
• Sourced CD34+ humanized mice
Humanized Immune Checkpoint Inhibitor Mouse Models

Get Started

Work with a team who believes in your research as much as you do.

Are you ready to start your preclinical studies? Partner with a collaborative oncology CRO that believes in your treatment as much as you do. Take the first step today and contact our experts.

Skip to content